Zobrazeno 1 - 10
of 274
pro vyhledávání: '"Robert, Wesolowski"'
Autor:
Kai C. C. Johnson, Ai Ni, Dionisia Quiroga, Ashley C. Pariser, Preeti K. Sudheendra, Nicole O. Williams, Sagar D. Sardesai, Mathew Cherian, Daniel G. Stover, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, Maryam Lustberg, Sachin Jhawar, Roman Skoracki, Robert Wesolowski
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract There is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society of Clinical Oncology Ca
Externí odkaz:
https://doaj.org/article/fc9fb37c438d44728b8717088153f8ae
Autor:
Jasmine S. Sukumar, Sagar Sardesai, Andy Ni, Nicole Williams, Kai Johnson, Dionisia Quiroga, Bhuvana Ramaswamy, Robert Wesolowski, Mathew Cherian, Daniel G. Stover, Margaret Gatti‐Mays, Ashley Pariser, Preeti Sudheendra, Mridula A. George, Maryam Lustberg
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit and clinical indi
Externí odkaz:
https://doaj.org/article/95ee2addb7d44134809b3c59d72db720
Autor:
Dionisia Quiroga DO, PhD, Robert Wesolowski MD, Sara Zelinskas BS, Ashley Pinette MD, Brooke Benner PhD, Emily Schwarz BS, Himanshu Savardekar BS, Courtney Johnson DO, Andrew Stiff MD, PhD, Lianbo Yu PhD, Erin Macrae MD, Maryam Lustberg MD, MPH, Ewa Mrozek MD, Bhuvaneswari Ramaswamy MD, William E. Carson MD
Publikováno v:
Cancer Control, Vol 31 (2024)
Objectives CpG ODN is a Toll-like receptor 9 agonist with immunotherapeutic potential for many cancer types, including aggressive breast cancers. There is strong interest in utilizing CpG ODN as an adjuvant to improve clinical efficacy of current tre
Externí odkaz:
https://doaj.org/article/c4a04ac8a9714a0fa31cf6f588fbd325
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7306 (2024)
Our study aims to address the methodological challenges frequently encountered in RNA-Seq data analysis within cancer studies. Specifically, it enhances the identification of key genes involved in axillary lymph node metastasis (ALNM) in breast cance
Externí odkaz:
https://doaj.org/article/2039628b0fc247f9a532242afaece9c0
Autor:
Kai Conrad Cecil Johnson, Daniel Goldstein, Jasmin Tharakan, Dionisia Quiroga, Mahmoud Kassem, Michael Grimm, Abdul Miah, Craig Vargo, Michael Berger, Preeti Sudheendra, Ashley Pariser, Margaret E. Gatti-Mays, Nicole Williams, Daniel Stover, Sagar Sardesai, Robert Wesolowski, Bhuvaneswari Ramaswamy, Gary Tozbikian, Patrick M. Schnell, Mathew A. Cherian
Publikováno v:
Oncology and Therapy, Vol 11, Iss 3, Pp 361-374 (2023)
Abstract Introduction The immunomodulatory impact of corticosteroids and concurrent chemotherapy is poorly understood within triple-negative breast cancer (TNBC). On a biochemical level, steroids have been linked to the signaling of chemotherapy-resi
Externí odkaz:
https://doaj.org/article/951fd11c96b2499b9c3ae9275fe18e77
Autor:
Nicole O. Williams, Dionisia Quiroga, Courtney Johnson, Adam Brufsky, Mara Chambers, Saveri Bhattacharya, Maria Patterson, Sagar D. Sardesai, Daniel Stover, Maryam Lustberg, Anne M. Noonan, Mathew Cherian, Darlene M. Bystry, Kasey L. Hill, Min Chen, Mitch A. Phelps, Michael Grever, Julie A. Stephens, Bhuvaneswari Ramaswamy, William E. Carson, Robert Wesolowski
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Heat shock protein 90 (HSP90) is a molecular chaperone required for stabilization of client proteins over-activated in triple-negative breast cancer (TNBC). Over-expression of HSP90 client proteins has been implicated in paclitaxel resist
Externí odkaz:
https://doaj.org/article/c53632218637477c91145bbc4eb4d598
Autor:
Kai CC Johnson, Michael Grimm, Jasmine Sukumar, Patrick M. Schnell, Ko Un Park, Daniel G. Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Robert Wesolowski, Nicole Williams, Sagar Sardesai, Ashley Pariser, Preeti Sudheendra, Gary Tozbikian, Bhuvaneswari Ramaswamy, Dureti Doto, Mathew A. Cherian
Publikováno v:
Breast, Vol 72, Iss , Pp 103591- (2023)
Inflammatory breast cancer (IBC) poses an ongoing challenge as rates of disease recurrence and mortality remain high compared to stage-matched controls. However, frontline therapy has evolved through the years, including the widespread use of neoadju
Externí odkaz:
https://doaj.org/article/98353212f4f4495c9d1e8802ab738b0c
Autor:
Kevin Conlon, Robert Wesolowski, Douglas G McNeel, John A Thompson, Rom Leidner, Andrea Wang-Gillam, Sumati Gupta, Nancy Lewis, George N Pavlakis, Lang Ho Lee, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Jessica A O’Keeffe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs). This first-in-human study investigated NIZ985, a recombin
Externí odkaz:
https://doaj.org/article/2886323ab834455e8737872e76203efc
Autor:
Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. Weirather, Anita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemothera
Externí odkaz:
https://doaj.org/article/d2b06f8f41a040519a09fe040f35b01e
Autor:
Sarah Asad, Adrienne Damicis, Yujing J. Heng, Kathryn Kananen, Katharine A. Collier, Elizabeth J. Adams, Kevin H. Kensler, Gabrielle M. Baker, Robert Wesolowski, Sagar Sardesai, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, A. Heather Eliassen, Susan E. Hankinson, Fred K. Tabung, Rulla M. Tamimi, Daniel G. Stover
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-16 (2022)
Abstract Background Breast tumor immune infiltration is clearly associated with improved treatment response and outcomes in breast cancer. However, modifiable patient factors associated with breast cancer immune infiltrates are poorly understood. The
Externí odkaz:
https://doaj.org/article/bfd391b7b4c543cc8e9f6b20a3f6dcf9